Canon Kabushiki Kaisha

Shionogi & Company Limited

Nissan Motor Company Limited

Ricoh Company, Ltd.

Agency of Industrial Science and Technology

Fuji Capsule Co., Ltd.

International Business Machines Corporation

Star Micronics Company Limited

Nihon Kohden Corporation

Koji Masuda

Satoshi Suzuki

Tomoyuki Ogawa

Takao Ogata

Kensaku Kusaka

Kazuhiro Hasegawa

Masanao Inagaki

Eiichi Kojima

Hiroyuki Tobinaga

Shigeo Kimura

Hisaaki Senba

Manami Masuda

Yoshinori Hayashi

Seizo Suzuki

Toru Yamada

Hiroyuki Kai

Yuji Sakemi

Yuji Bessho

Fujio Mizukami

Manabu Katou

Naoki Yoshikawa

Hidekazu Maruta

Shiro Kida

Naotake Kobayashi

Shuichi Sugiyama

Shinji Hanada

Mitsuhiro Yonehara

Mado Nakajima

Naoki Nishimura

Takayuki Ishikawa

Kenji Kato

Tomoyuki Sakamaki

Akihiko Sato

Yusuke Ishida

Hiroyuki Suhara

Masao Tokunari

Tadashi Fukuda

Tsuyoshi Watanabe

Fumitake Hirobe

Takayuki Ishihara

Matsuomi Nishimura

Kota Arimoto

Manabu Takano

Yoshiyuki Shimokawa

Takeo Yamamoto

Nobuyuki Tanaka

Akira Kugimiya

Kazuhiko Watanabe

Noriyuki Kurose

Hsiang Han Hsu

Hideki Fujita

Takahiro Noguchi

Yoshiyuki Eto

Yuta Inoue

Tsuneji Sano

Nobuo Chomei

Satoru Tanaka

Kazuki Tanaka

Maki Kamikubo

Terukazu Kato

Junichi Mine

Rie Hirayama

Yosuke Kondo

Takuya Ikeda

Keiko Igarashi

Tetsuo Ito

Keiichi Sawamura

Yusuke Ichihashi

Hyuga Masu

Kyohei Hayashi

Rikiya Tanabe

Takuji Nakatani

Motohiro Kawamura

Chiemi Hayashi

Akihiko Hayano

Yuki Obatake

Yoshihiko Watanabe

Satoshi Kasuya

Mikayo Hayashi

Hiroshi Nakano

A soft capsule film composition, comprising: (A) a native gellan gum; (B) one or more hydrophilic polysaccharides; (C) a starch or modified starch; (D) a plasticizer; and (E) water, wherein a gelling agent other than the native gellan gum and the one or more hydrophilic polysaccharides is not an essential component. The soft capsule film composition shortens drying time at room temperature, suppresses the stickiness of the surface of a film sheet, imparts film sheet strength which can withstand continuous production in factory manufacturing with a rotary die filling machine or the like, and enables the manufacture of a good soft capsule with high adhesiveness. For this reason, the soft capsule produced using the soft capsule film composition can be utilized for various uses such as drugs, quasi drugs, cosmetics, and foods.

Soft capsule film composition

An optical connector device is provided. The optical connector device includes a semiconductor package including a receptacle and a lid. The optical connector device also included an adapter attached to the lid of the semiconductor package, and a connector removably attached to the adapter. The adapter includes a convex part adapted to fit into an adapter opening of the lid, an adapter recess adapted to accommodate at least a portion of the connector, and a first retainer in the adapter recess to removably attach the connector to the adapter at a predetermined position. The connector includes an optical fiber array corresponding to the receptacle and extending in a vertical direction with respect to a plane of the semiconductor package, a second retainer used in conjunction with the first retainer, and a biasing member to bias a portion of the connector toward the semiconductor package.

Optical connector device with lid

Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein

Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect

Provided are a novel compound having an antagonistic activity for the P2Xreceptor, and a pharmaceutical composition having an antagonistic activity for the P2Xreceptor. A compound represented by Formula (I): wherein Zis C(R) or the like; Ris a hydrogen atom or the like; Zis C(R)(R) or the like; the dashed line represents the presence or absence of a bond; when the dashed line represents the presence of a bond, then Ris absent; Rand Rare each independently a hydrogen atom or the like; Ring Q is a substituted or unsubstituted 5-membered non-aromatic heterocycle or the like; Yis O or the like; Ris a group represented by the formula: &#x2014;(C(R)(R))&#x2014;R; Ris a hydrogen atom or the like; Rand Ris each independently a hydrogen atom or the like; Ris substituted or unsubstituted aromatic carbocyclyl or the like; X is N(R) or the like; Ris a hydrogen atom or the like; Ris substituted or unsubstituted aromatic carbocyclyl or the like; n is an integer from 0 to 4; and m is an integer from 0 to 4, or a pharmaceutically acceptable salt thereof.

Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same

Novel compounds having a D3 receptor antagonistic effect are provided. The compound represented by Formula (IA)': wherein A is S or O; Ris substituted or unsubstituted alkyloxy or the like, Rto Rare each independently hydrogen atoms or the like, ring B is a 4- to 8-membered non-aromatic carbocycle or the like, Ris each independently halogen or the like, r is an integer of 0 to 4, Ris substituted or unsubstituted aromatic heterocyclyl or the like,or a pharmaceutically acceptable salt thereof.

Condensed ring compounds having dopamine D3 receptor antagonistic effect

Novel compounds having a D3 receptor antagonistic activity are provided. The compound represented by Formula (I): wherein Ring A is a non-aromatic heterocycle or the like substituted with substituted or unsubstituted aromatic heterocyclyl or the like; Rto Rare each independently a hydrogen atom or the like; n is an integer of 0 to 3; Ring B is a non-aromatic carbocycle or the like; Ris each independently halogen or the like; r is an integer of 0 to 4; -L- is &#x2014;N(R)&#x2014;C(&#x2550;O), or the like; Ris a hydrogen atom or the like; Ris substituted or unsubstituted aromatic heterocyclyl or the like,or a pharmaceutically acceptable salt thereof.

Cyclic compound having dopamine D3 receptor antagonistic effect

Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): whereinring A is a heterocycle, Xis each independently CRR, Xis each independently CRR, Yand Yare each independently a carbon atom or a nitrogen atom,L is &#x2014;N(R)&#x2014;C(&#x2550;O)&#x2014; or the like, W is cyclyl or the like, Rand Rare each independently substituted or unsubstituted alkyl or the like, R, R, Rto R, and Rare each independently hydrogen atoms or the like,p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.

Provided are a novel compound having an antagonistic activity for the P2Xreceptor, and a pharmaceutical composition having an antagonistic activity for the P2Xreceptor. The compound represented by Formula (I): wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.

Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): 

The invention provides a machine tool capable of facilitating a process of switching product ejecting apparatuses. The machine tool comprises a spindle which rotates a workpiece around an axis of the spindle, an actuator which reciprocates a rod arranged parallel to the axis of the spindle, and a coupler switched between a coupling position and a standby position. The coupler connects the rod and an ejecting shaft inserted in the spindle when held in the coupling position. The coupler is not connected to at least the ejecting shaft when held in the standby position. The ejecting shaft along with the coupler is moved in the direction of the axis of the spindle according to reciprocation of the rod when the coupler is held in the coupling position.

Machine tool

An object is to provide a method of manufacturing a seamless soft capsule that is enteric and excellent in formulation properties. An enteric seamless soft capsule is manufactured by the following steps (a) and (b): (a) preparing an enteric capsule shell liquid comprising gelatin and low methoxy pectin having a degree of esterification of 0 to 40% and a degree of amidation of 0 to 25%, the enteric capsule shell liquid having a viscosity at 50&#xb0; C. of 60 to 127 mPa&#xb7;s; and (b) encapsulating capsule fills with the enteric capsule shell liquid prepared in the step (a) by dripping. Preferably, the jelly strength of the gelatin is 180 to 330 Bloom, an aqueous solution of the low methoxy pectin at a concentration of 2 mass % has a viscosity at 35&#xb0; C. of 8 to 15 mPa&#xb7;s, and the enteric capsule shell liquid comprises 10 to 20 parts by mass of the low methoxy pectin per 100 parts by mass of gelatin.

Method of manufacturing enteric seamless soft capsule

Disclosed is a compound which is useful as an endothelial lipase inhibitor. A pharmaceutical composition having inhibitory activity on endothelial lipase comprising a compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof,wherein

Acetic acid amide derivative having inhibitory activity on endothelial lipase

Disclosed is an adamantanamine derivative which is useful as a significant intermediate of an 11&#x3b2;HSD-1 inhibitor. Disclosed is a compound represented by the formula (II): wherein Ris a group represented by the formula: &#x2014;(CRR)m-NR&#x2014;Ror the like.

Adamantanamine derivative

A compound represented by the formula: or its pharmaceutically acceptable salt. Ring A is aromatic carbocycle or aromatic heterocycle, Z is &#x2014;O&#x2014; or &#x2014;S&#x2014;, Ris hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like, Rand Rare each independently hydrogen, halogen, hydroxy or the like, Ris a group represented by the formula: &#x2014;(CRR)&#x2014;R, Rand Rare each independently hydrogen, halogen, hydroxy or the like, n is an integer of 0 to 3, Ris carboxy, cyano, substituted or unsubstituted alkyl or the like, Ris halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like, and m is an integer of 0 to 3.

Oxadiazole derivative having endothelial lipase inhibitory activity

Disclosed is a compound which is useful as an 11&#x3b2;-hydroxysteroid dehydrogenase type 1 inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof,wherein Ring A is a group represented by the formula: 

Nitrogen-containing heterocyclic derivative having 11&#x3b2;-hydroxysteroid dehydrogenase type I inhibitory activity

Growing community of inventors

Tokyo, Japan

Koji Masuda